Back to results
US 12,053,503 B2Granted
Antigenic epstein barr virus polypeptides
AssigneeSanofi
InventorsGary J. Nabel, Chih-Jen Wei, Laura Nguyen, Kurt Swanson, Te-Hui Chou
Life of this patent
Estimating the term…
Abstract
This disclosure relates to antigenic EBV polypeptides and their use in eliciting antibodies against EBV. Also disclosed are antigenic polypeptides comprising an EBV polypeptide and a ferritin protein.
Claims46
A polypeptide comprising an Epstein Barr Virus (EBV) gL polypeptide, an EBV gH polypeptide, and an EBV gp42 polypeptide, wherein the polypeptide comprises the amino acid sequence of amino acids 31-1156 of SEQ ID NO:
- 242.
A composition comprising:
- (a) a first polypeptide consisting of the amino acid sequence of amino acids 31-1156 of SEQ ID NO:
- 242 and a ferritin protein amino acid sequence that is at least 97% identical to the amino acid sequence of SEQ ID NO:
- 208, wherein the ferritin protein amino acid sequence is C-terminal to the amino acid sequence of amino acids 31-1156 of SEQ ID NO:
- 242 within the first polypeptide;
- and
- (b) a second polypeptide consisting of the amino acid sequence of SEQ ID NO:
- 1 lacking the leader sequence.
4 more elements
A polypeptide comprising the amino acid sequence of SEQ ID NO:
- 1 lacking the leader sequence.
A polypeptide consisting of the amino acid sequence of amino acids 31-1156 of SEQ ID NO:
- 242 and a ferritin protein amino acid sequence consisting of amino acids 1157-1329 of SEQ ID NO:
- 242 with one amino acid substitution, wherein the ferritin protein amino acid sequence is C-terminal to the amino acids 31-1156 of SEQ ID NO:
- 242 within the polypeptide.
Dependencies are inferred from the claim text.